Tsuboi, M. Et Al. 2023. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. NEW ENGLAND JOURNAL OF MEDICINE , vol.389, no.2 , 137-147.

Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohe, C., ... Wang, J.(2023). Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. NEW ENGLAND JOURNAL OF MEDICINE , vol.389, no.2, 137-147.

Tsuboi, Masahiro Et Al. "Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC," NEW ENGLAND JOURNAL OF MEDICINE , vol.389, no.2, 137-147, 2023

Tsuboi, Masahiro Et Al. "Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC." NEW ENGLAND JOURNAL OF MEDICINE , vol.389, no.2, pp.137-147, 2023

Tsuboi, M. Et Al. (2023) . "Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC." NEW ENGLAND JOURNAL OF MEDICINE , vol.389, no.2, pp.137-147.

@article{article, author={Masahiro Tsuboi Et Al. }, title={Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC}, journal={NEW ENGLAND JOURNAL OF MEDICINE}, year=2023, pages={137-147} }